51 reports of this reaction
1.6% of all PIOGLITAZONE HYDROCHLORIDE reports
#10 most reported adverse reaction
PNEUMONIA is the #10 most commonly reported adverse reaction for PIOGLITAZONE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 51 FDA adverse event reports linking PIOGLITAZONE HYDROCHLORIDE to PNEUMONIA. This represents approximately 1.6% of all 3,283 adverse event reports for this drug.
Patients taking PIOGLITAZONE HYDROCHLORIDE who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is a less commonly reported adverse event for PIOGLITAZONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to pneumonia, the following adverse reactions have been reported for PIOGLITAZONE HYDROCHLORIDE:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 51 FDA reports for PIOGLITAZONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 1.6% of all adverse event reports for PIOGLITAZONE HYDROCHLORIDE, making it a notable side effect.
If you experience pneumonia while taking PIOGLITAZONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.